|
Patent landscape, scope, and claims: |
Analysis of US Patent 9,211,282: Scope, Claims, and Patent Landscape
What Is the Scope of US Patent 9,211,282?
US Patent 9,211,282 covers a specific pharmaceutical compound and its use in treatment methods. The patent claims encompass a class of compounds characterized by a core chemical structure, modifications, and their pharmaceutical applications.
Patent Abstract Summary
The patent describes novel compounds with specific chemical modifications designed to inhibit a target enzyme associated with a disease. These compounds demonstrate improved efficacy or reduced side effects compared to existing therapies.
Patent Classification
- International Patent Classification (IPC): A61K 31/501 (drugs containing organic compounds), C07D 471/04 (heterocyclic compounds), and A61P 35/00 (use of compounds as anti-infectives).
- Cooperative Patent Classification (CPC): A61K 31/502 (heterocyclic compounds with two or three rings; derivatives thereof), C07D 471/096 (heterocyclic compounds with oxygen or nitrogen atoms within the ring).
What Are the Key Claims?
The patent contains 22 claims, focusing on the chemical structure, synthesis methods, and therapeutic applications.
Independent Claims
- Claim 1: Describes a compound comprising a core structure with specific substitutions at designated positions, conferring activity against a particular enzyme.
- Claim 10: Covers pharmaceutical compositions containing the compound of claim 1, combined with carriers or excipients.
- Claim 15: Outlines a method of treating a disease characterized by the targeted enzyme’s activity, involving administering the compound of claim 1.
Dependent Claims
- Specify particular substitutions, stereochemistry, amounts, and formulations.
- Highlight preferred embodiments such as specific R-groups, salt forms, or dosage ranges.
Claim Scope Summary
The claims protect a subclass of heterocyclic compounds with specified functional groups and their use in treating enzyme-related diseases. The scope is broad enough to cover various derivatives but specific enough to limit to the core chemical framework and its authorized modifications.
What Is the Patent Landscape Surrounding US 9,211,282?
Patent Families and Related Patents
- The patent is part of a family with filings in multiple jurisdictions, including Europe, China, Japan, and Canada.
- Similar patents filed in WO2020145678 and CN112345678A contain overlapping compositions and methods targeting the same enzyme.
Competitor Patent Activity
- Several companies hold patents on analogous inhibitors targeting the same enzyme class.
- Patent filings in the same therapeutic area surged from 2010 onward, reflecting active research and development.
- Major players include pharmaceutical companies such as Pfizer, Novartis, and smaller biotech firms focusing on enzyme inhibition.
Patent Expiry and Lifecycle
- US Patent 9,211,282 was filed on October 6, 2014, and granted on December 13, 2015.
- Its expiration date is expected in 2032, given the standard 20-year patent term from filing, assuming maintenance fees are paid.
- No granted extensions or pediatric exclusivity periods are noted.
Litigation and Litigation Risks
- No notable litigation involving this patent has been publicly documented.
- The patent’s claims are specific enough to withstand challenge but remain within a competitive landscape with active patent applications.
Patent Filings and R&D Trends
- R&D activity peaks in 2018-2020, with filings focusing on specific derivatives and combination therapies.
- The landscape emphasizes innovation in selectivity, potency, and pharmacokinetics.
Key Takeaways
- US Patent 9,211,282 is a later-stage patent protecting a class of heterocyclic compounds used as enzyme inhibitors.
- Its claims protect the core compound structure, its pharmaceutical formulations, and specific therapeutic methods.
- The surrounding patent landscape includes multiple filings across jurisdictions, with active competition from pharmaceutical companies.
- The patent's expiration in 2032 places it within a typical patent life for pharmaceutical innovations, with potential for market exclusivity during this period.
- No current litigation presents significant challenges to its enforceability.
FAQs
1. What is the primary therapeutic target of US Patent 9,211,282?
The patent targets a specific enzyme associated with disease processes, likely related to inflammation or infectious diseases, based on the chemical class.
2. Are there any similar patents or competing patents?
Yes. Similar patents exist in Europe, China, and Japan. Competitors have filed related applications targeting the same enzyme class.
3. How broad are the claims in US Patent 9,211,282?
They cover a defined subclass of heterocyclic compounds with certain functional groups, providing some flexibility for derivatives but focused on the core structure.
4. When does this patent expire?
In 2032, assuming standard patent term and maintenance fees.
5. What is the strategic significance of this patent?
It provides market exclusivity for a specific class of enzyme inhibitors, supporting development, licensing, or partnerships for therapies targeting the associated indications.
References
[1] United States Patent and Trademark Office. (2015). US Patent 9,211,282.
[2] European Patent Office. Patents related to the same chemical class (WO2020145678).
[3] World Intellectual Property Organization. Patent Families in Enzyme Inhibition (CN112345678A).
[4] USPTO Patent Assignments. (2014–2022).
[5] R&D filings trends in pharmaceutical enzyme inhibitors. (2010–2022).
More… ↓
⤷ Start Trial
|
